article thumbnail

Lupin acquires anti-diabetes trademarks from Boehringer Ingelheim to strengthen portfolio

Express Pharma

On December 13, 2024, Lupin, a global pharmaceutical company, announced the acquisition of anti-diabetes trademarks GIBTULIO, GIBTULIO MET, and AJADUO from Boehringer Ingelheim International GmbH. The move is aimed at strengthening Lupins diabetes portfolio in India. In addition, 25 million people are pre-diabetic.

Diabetes 105
article thumbnail

STAT+: How AI can distort clinical decision-making to prioritize profits over patients

STAT

More than a decade ago, Ken Mandl was on a call with a pharmaceutical company and the leader of a social network for people with diabetes. The drug maker was hoping to use the platform to encourage its members to get a certain lab test.    The test could determine a patient’s need for a helpful drug.

Hospitals 221
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Eli Lilly reports tirzepatide MASH success during Q4 earnings

STAT

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Diabetes 362
article thumbnail

STAT+: Pharmalittle: WHO pandemic accord may force pharma to disclose prices; FDA OKs first therapy to delay type 1 diabetes

STAT

Pharmaceutical companies could be made to disclose prices and deals for products they make to fight future global health emergencies, under new rules that would govern a World Health Organization-backed pandemic accord , Reuters reports. The first therapy that delays the onset of type 1 diabetes received approval from the U.S.

Diabetes 244
article thumbnail

STAT+: Bernie Sanders may have reached the limits of his pharma pressure campaign

STAT

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. Sanders (I-Vt.)

Diabetes 341
article thumbnail

STAT+: What will Novo’s VC do with its influx of cash? Don’t expect obesity investments

STAT

The Danish pharmaceutical company Novo Nordisk has shepherded all kinds of medical innovation in the 110 years since it was founded. But the booming success of its diabetes and obesity drug is unlike anything executives have seen before. The company’s mid-year operating profit jumped from 37.5

Diabetes 290
article thumbnail

STAT+: Novo Holdings to purchase drug manufacturer Catalent for $16.5 billion, a deal that could expand Wegovy production

STAT

billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.     Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally.

Diabetes 351